These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25091467)

  • 1. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.
    Fichter CD; Gudernatsch V; Przypadlo CM; Follo M; Schmidt G; Werner M; Lassmann S
    J Mol Med (Berl); 2014 Nov; 92(11):1209-23. PubMed ID: 25091467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas.
    Timme S; Ihde S; Fichter CD; Waehle V; Bogatyreva L; Atanasov K; Kohler I; Schöpflin A; Geddert H; Faller G; Klimstra D; Tang L; Reinheckel T; Hauschke D; Busch H; Boerries M; Werner M; Lassmann S
    Oncogene; 2014 Jun; 33(25):3256-66. PubMed ID: 23912451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells.
    Fichter CD; Herz C; Münch C; Opitz OG; Werner M; Lassmann S
    BMC Cell Biol; 2011 Apr; 12():13. PubMed ID: 21470402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
    Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
    Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
    Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
    Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
    Zhang J; Gelman IH; Katsuta E; Liang Y; Wang X; Li J; Qu J; Yan L; Takabe K; Hochwald SN
    Cell Mol Gastroenterol Hepatol; 2019; 8(1):37-60. PubMed ID: 30836148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma.
    Chai AW; Cheung AK; Dai W; Ko JM; Ip JC; Chan KW; Kwong DL; Ng WT; Lee AW; Ngan RK; Yau CC; Tung SY; Lee VH; Lam AK; Pillai S; Law S; Lung ML
    Oncotarget; 2016 Nov; 7(48):78859-78871. PubMed ID: 27793011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rho GTPase RhoE exerts tumor-suppressing effects in human esophageal squamous cell carcinoma via negatively regulating epidermal growth factor receptor.
    Wang H; Wang Y; Liang B; He F; Li Y; Che J; Li X; Zhao H; Shi G
    J Cancer Res Ther; 2016 Oct; 12(Supplement):60-63. PubMed ID: 27721256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
    Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
    J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer.
    Kang J; Guo Z; Zhang H; Guo R; Zhu X; Guo X
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
    Mimura K; Kono K; Maruyama T; Watanabe M; Izawa S; Shiba S; Mizukami Y; Kawaguchi Y; Inoue M; Kono T; Choudhury A; Kiessling R; Fujii H
    Int J Cancer; 2011 Nov; 129(10):2408-16. PubMed ID: 21207425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
    Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
    J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
    Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
    Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells.
    Hoque M; Elmaghrabi YA; Köse M; Beevi SS; Jose J; Meneses-Salas E; Blanco-Muñoz P; Conway JRW; Swarbrick A; Timpson P; Tebar F; Enrich C; Rentero C; Grewal T
    FEBS J; 2020 Jul; 287(14):2961-2978. PubMed ID: 31869496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
    Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.